Provention Bio's Tzield (teplizumab), which the US Food and Drug Administration greenlighted in November 2022, is a CD3-directed monoclonal antibody injection for patients who are asymptomatic but progressing toward clinical diabetes. But while there are promising screening methods, doctors are waiting on updates from implementation studies and guidelines bodies before incorporating such tests into routine patient care. NEW YORK – The landmark approval of a drug to delay the onset of type 1 diabetes has called attention to efforts to identify people who are at risk of developing the disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |